Cyprus Country Drug Report 2019

Public expenditure

Understanding the costs of drug-related actions is an important aspect of drug policy. Some of the funds allocated by governments to expenditure on tasks related to drugs are identified as such in the budget (‘labelled’). Often, however, most drug-related expenditure is not identified (‘unlabelled’), especially in the field of supply reduction initiatives, and must be estimated using modelling approaches.

Drug-related public expenditure has been estimated for more than a decade, and the methodology used is currently being revised and improved. In 2017, total drug-related expenditure amounted to 0.08 % of Cyprus’s gross domestic product (GDP). The total expenditure of approximately EUR 15 million was divided into three main areas: law enforcement, healthcare and education.

#


Cyprus main page

Methodological note: Analysis of trends is based only on those countries providing sufficient data to describe changes over the period specified. The reader should also be aware that monitoring patterns and trends in a hidden and stigmatised behaviour like drug use is both practically and methodologically challenging. For this reason, multiple sources of data are used for the purposes of analysis in this report. Caution is therefore required in interpretation, in particular when countries are compared on any single measure. Detailed information on methodology and caveats and comments on the limitations in the information set available can be found in the EMCDDA Statistical Bulletin.